← Back to All US Stocks

Nanobiotix S.A. (NBTX) Fundamental Analysis & AI Grade 2026

NBTX Nasdaq Pharmaceutical Preparations I0 CIK: 0001760854
Recently Updated • Analysis: May 28, 2026 • SEC Data: 2026-05-28

Nanobiotix S.A. (NBTX) Financial Metrics & Key Ratios

Revenue
N/A
Net Income
N/A
EPS (Diluted)
$0.00
Free Cash Flow
N/A
Total Assets
N/A
Cash Position
N/A

💡 AI Analyst Insight

The current ratio below 1.0x warrants monitoring of short-term liquidity.

NBTX Profit Margin, ROE & Profitability Analysis

Gross Margin N/A
Operating Margin N/A
Net Margin N/A
ROE N/A
ROA N/A
FCF Margin N/A

NBTX vs Healthcare Sector: How Nanobiotix S.A. Compares

How Nanobiotix S.A. compares to Healthcare sector averages

Net Margin
NBTX 0.0%
vs
Sector Avg 12.0%
NBTX Sector
ROE
NBTX 0.0%
vs
Sector Avg 15.0%
NBTX Sector
Current Ratio
NBTX 0.0x
vs
Sector Avg 2.0x
NBTX Sector
Debt/Equity
NBTX 0.0x
vs
Sector Avg 0.6x
NBTX Sector

Sector benchmarks are approximate industry averages. Actual sector performance may vary.

Is Nanobiotix S.A. Stock Overvalued? NBTX Valuation Analysis 2026

Based on fundamental analysis, Nanobiotix S.A. has mixed fundamental signals relative to the Healthcare sector in 2026.

Return on Equity
N/A
Sector avg: 15%
Net Profit Margin
N/A
Sector avg: 12%
Revenue Growth
N/A
Year-over-year
Debt/Equity
N/A
Sector avg: 0.6x

Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.

Nanobiotix S.A. Balance Sheet: NBTX Debt, Cash & Liquidity

Current Ratio
N/A
Quick Ratio
N/A
Debt/Equity
N/A
Debt/Assets
0.0%
Interest Coverage
N/A
Long-term Debt
N/A

NBTX Revenue Growth, EPS Growth & YoY Performance

Revenue Growth
N/A
Year-over-year
Net Income Growth
N/A
Year-over-year
EPS Growth
N/A
Earnings per share
FCF Margin
N/A
Free cash flow / Revenue

NBTX SEC Filings: Latest 10-K & 10-Q Analysis

Access official SEC EDGAR filings for Nanobiotix S.A. (CIK: 0001760854)

📋 Recent SEC Filings

Date Form Document Action
Nov 16, 2023 SC 13G d568772dsc13g.htm View →
Nov 8, 2023 SC 13G qia-sc13g_110223.htm View →
Jan 27, 2021 SC 13G Nanobiotix31122020.txt View →
Dec 28, 2020 SC 13G d40589dsc13g.htm View →

Frequently Asked Questions about NBTX

What is the AI rating for NBTX?

Nanobiotix S.A. (NBTX) has an AI grade of N/A with 0% confidence, based on fundamental analysis of SEC EDGAR filings.

What are NBTX's key strengths?

Claude: Analysis in progress.

What are the risks of investing in NBTX?

Claude: Analysis in progress.

What is NBTX's revenue and growth?

Nanobiotix S.A. reported revenue of N/A.

Does NBTX pay dividends?

Nanobiotix S.A. does not currently pay dividends.

Where can I find NBTX SEC filings?

Official SEC filings for Nanobiotix S.A. (CIK: 0001760854) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.

What is NBTX's EPS?

Nanobiotix S.A. has a diluted EPS of $0.00.

How is the AI analysis conducted?

Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.

What is NBTX's fundamental grade?

Based on our AI fundamental analysis in May 2026, Nanobiotix S.A. has a N/A grade with 0% confidence. Review the strengths and risks sections above for full context. This is not investment advice.

Is NBTX stock overvalued or undervalued?

Valuation metrics for NBTX: ROE of N/A (sector avg: 15%), net margin of N/A (sector avg: 12%). Compare these metrics with sector averages to assess valuation.

What is NBTX's AI grade for 2026?

Our dual AI analysis gives Nanobiotix S.A. a combined N/A grade for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.

What is NBTX's free cash flow?

Nanobiotix S.A.'s operating cash flow is N/A, with capital expenditures of N/A.

How does NBTX compare to other Healthcare stocks?

Vs Healthcare sector averages: Net margin N/A (avg: 12%), ROE N/A (avg: 15%), current ratio N/A (avg: 2).

Top Rated Stocks
AAPL 92% MSFT 92% FAST 92% ANET 88% RDDT 88% KNSL 88% MGRE 88% FIZZ 88% DECK 87% NVDA 87%
Sector: All Healthcare Stocks →
Disclaimer: This analysis is generated by Claude AI (Anthropic) and ChatGPT (OpenAI) based on publicly available SEC EDGAR filings. It does not include stock price data and should not be considered financial advice. All fundamental data is sourced from SEC public domain filings. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.
Data Source: SEC EDGAR | Analysis Date: May 28, 2026 | Data as of: 2026-05-28 | Powered by Claude AI